Geographic and Temporal Trends of Transmitted HIV-1 Drug Resistance Among Antiretroviral-Naive Subjects Screening for Two Clinical Trials in North America and Western Europe
Geographic and Temporal Trends of Transmitted HIV-1 Drug Resistance Among Antiretroviral-Naive Subjects Screening for Two Clinical Trials in North America and Western Europe
复制标题
DOI：
10.1310/hct1002-94
复制
发表时间：
2009-03-01
影响因子：
--
通讯作者：
King, Martin S.
中科院分区：
文献类型：
--
作者：
Rahim, Sibtain;Fredrick, Linda M.;King, Martin S.
目的：确定未接受过抗逆转录病毒 (ARV) 治疗的 HIV-1 感染受试者中传播耐药性 (TDR) 的患病率，这些受试者按地理区域和时间进行了两项临床试验的筛选。方法：研究 M03-613 和 M05-730 分别在 2004 年和 2005-2006 年筛查未接受过 ARV 的受试者。使用群体测序进行筛选耐药基因型分析，评估 HIV-1 蛋白酶和逆转录酶 (RT) 中 39 个氨基酸位置的耐药突变 (DRM) 流行率，并在地理区域和日历年之间进行比较。结果：在 913 名受试者中，北美的 DRM 患病率高于西欧，包括任何 DRM（13.6% vs. 6.8%，p
Purpose: To determine the prevalence of transmitted drug resistance (TDR) in antiretroviral (ARV)-naive HIV-1-infected subjects who were screened for two clinical trials by geographic region and time. Methods: Studies M03-613 and M05-730 screened ARV-naive subjects in 2004 and 2005-2006, respectively. Screening drug resistance genotype assays were performed using population sequencing, and prevalence of drug resistance mutations (DRMs) was assessed at 39 amino acid positions in HIV-1 protease and reverse transcriptase (RT) and compared between geographic regions and calendar years. Results: In 913 subjects, the prevalence of DRMs was higher in North America than in Western Europe, including any DRM (13.6% vs. 6.8%, p